Team:Tokyo Tech/Project/Artificial Cooperation System/Cm assay


Revision as of 03:06, 28 October 2010 by Kitano (Talk | contribs)

iGEM Tokyo Tech 2010 "E.coli with Humanity"

3-2 resistance gene activation device



We succeeded in constructing and characterizing a NEW Biobrick device of chloramphenicol resistance (CmR) gene (BBa_K395162) which is activated by lux activation promoter. We found that the device is activated by LuxR/3OC6HSL complex and that the cell introduced the part was able to survive even in high chloramphenicol concentration (750 ug/ml) in the presence of 3OC6HSL.



Chloramphenicol is a well known antibiotic that is effective against a wide variety of Gram-positive and Gram-negative bacteria including E. coli. Chloramphenicol stops bacterial growth because it is a protein synthesis inhibitor, which prevents peptide bond formation. When chloramphenicol is added, the synthesis of proteins is inhibited in bacteria which don't express chloramphenicol resistance gene. Then their growth stops and the number of the cell is going to decrease. However, bacteria which express chloramphenicol resistance gene are able to survive in the existence of chloramphenicol. These characteristics indicates that chloramphenicol and chloramphenicol resistance gene can be used for population control which is important to construct the Artificial Cooperation System


  • The results of 20 hours incubation after addition of chloramphenicol shows that Plux-CmR grew when 3OC6HSL is added , while Plux-CmR in the absence of 3OC6HSL was not able to grow.

On the other hand, The cells introduced the promoterless device were not able to grow independently of 3OC6HSL. In the case of the device that had constitutive promoter, the growth of the cells introduced the device were quite slow compared with that of Plux. However, there was no significant difference between in the presence and the absence of 3OC6HSL.

Fig.3-3-2 Growth curve of the cell introduced PlacIq-CmR (BBa_K395165,blue curves), Plux-CmR (BBa_K395162,Red curves), or promoterless-CmR (BBa_K395160,green curves) with or without AHL (3OC6HSL).
This work is done by Yusuke Kaneta.


From the results, when chloramphenicol was added, the cells introduced Plux-CmR were able to grow because LuxR/3OC6HSL complex activated Plux. This means we found the conditions that integrants were able to survive only in the presence of 3OC6HSL.

Material and Method

construction Plux-CmR on pSB6A1

A part, RBS-CmR was cut from BBa_P1004 by PCR and put into pSB6A1. Next RBS-CmR on pSB6A1 and Plux (BBa_R0062) was cut at EcoRI /Xba site and EcoRI/SpeI site respectively. Then we ligated two parts.

Construction of E. coli strain DH5α

Competent cells with luxR gene on pSB3K3 were constructed. Afterward, Plux-CmR on pSB6A1 was introduced into the cells.

The growth assay

In order to follow up the growth of the cells which Plux-CmR was introduced into, the change of O.D. (590nm) in both the presence and the absence of 3OC6HSL was measured.

  1. Plux-CmRBBa_K395162
  2. constitutive promoter (PlacIq)-CmR (positive control)BBa_K395165
  3. promoterless-CmR (negative control)BBa_K395160

LB medium were used for liquid culture. Antibiotics (ampicillin (Amp), kanamycin (Kan), and chloramphenicol (Cm)) were dissolved in distillation water and stored as 25 mg/ml, whose final concentration in the medium was 50ug/ml, 30ug/ml, and 750ug/ml respectively.

  1. The seed cultures of the samples were inoculated from glycerol stock solution and grown separately overnight at 37°C in LB medium containing Amp&Kan.
  2. Then, we diluted the cultures 100 folds by two types of 3 ml of fresh medium. One type of the medium contains 3OC6HSL (final concentration:100nM). Another contains DMSO as control. Both of the cultures were incubated at 37°C
  3. After 1 hour from dilution, each culture was separated to two new tubes. Then it was added 1.5 ml LB medium each containing Cm (final concentration:750ug/ml), Amp, Kan,3OC6HSL or DMSO
  4. Measured O.D.590 every an hour, up to 20 hours from dilution.


  1. Ying-jin Yuan et al PLoS 2010, e10619
  2. W. Shaw, et al Br. Med. Bull. 1984, 40, 36.